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Deletion 5q or monosomy 5 (-5/5q-) in acute myeloid leukemia(AML)  is a common high-risk feature that is referred to allogeneicstem cell transplantation. However, -5/5q- is frequently associated
with other high-risk cytogenetic aberrations such as complex karyotype,
monosomal karyotype, monosomy 7 (-7), or 17p abnormalities (abn (17p)),
the significance of which is unknown. In order to address this question, we
studied adult patients with AML harboring -5/5q- having their first allo-
geneic transplantation between 2000 and 2015. Five hundred and one
patients with -5/5q- have been analyzed. Three hundred and  thirty-eight
patients (67%) were in first remission and 142 (28%) had an active disease
at time of allogeneic transplantation. The 2-year probabilities of overall sur-
vival and leukemia-free survival were 27% and 20%, respectively. The 2-
year probability of treatment-related mortality was 20%. We identified
four different cytogenetic groups according to additional abnormalities
with prognostic impact: -5/5q- without complex karyotype, monosomal
karyotype or abn(17p), -5/5q- within a complex karyotype, -5/5q- within a
monosomal karyotype and the combination of -5/5q- with abn(17p). In
multivariate analysis, factors associated with worse overall survival and
leukemia-free survival across the four groups were active disease, age,
monosomal karyotype, and abn(17p). The presence of -5/5q- without
monosomal karyotype or abn(17p) was associated with a significantly bet-
ter survival rate while -5/5q- in conjunction with monosomal karyotype or
abn(17p) translated into a worse outcome. The patients harboring the com-
bination of -5/5q- with abn(17p) showed very limited benefit from allo-
geneic transplantation. 
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ABSTRACT
Introduction
Allogeneic stem cell transplantation (SCT) is a standard
of care in patients with intermediate and high-risk acute
myeloid leukemia (AML).1,2 High-risk AML is mainly
defined by the presence of determined poor-risk cytoge-
netic abnormalities at diagnosis together with specific
mutational events.3-6  In general, conventional post-remis-
sion high-dose chemotherapy is not capable of eradicating
the leukemic-initiating stem-cell population of high-risk
AML, harboring strong chemoresistance mechanisms,7
and only the potent graft-versus-leukemia (GvL) effect
mediated by SCT may provide the capability to eradicate
this cell population and overcome the poor prognosis of
these high-risk AML subtypes, as previously demonstrat-
ed.2,8-10 Among the heterogeneous group of high-risk AML,
prognosis can be further stratified based on specific genet-
ic abnormalities, and the potential benefit of SCT differs
among these diverse AML subtypes.11 Monosomy 5 or
deletion of the long arm of chromosome 5 (-5/5q) has
been part of the definition of high-risk AML for many
years.12 Furthermore, monosomal karyotype (MK)
described ten years ago referred to a cytogenetic risk cate-
gory constantly associated with a very poor outcome.13,14
Within this subgroup, patients harboring a single mono-
somy, including monosomy 5, have a relatively better out-
come than patients with two or more monosomies.15 We
recently reported the outcome of SCT in 125 patients with
AML and abnormalities of the short arm of chromosome
17 [abn(17p)] transplanted in first remission. The addition
of -5/5q- to abn(17p) translated into a very bad outcome
with a 2-year leukemia-free survival (LFS) of about 12%.16
The benefit of SCT in this subgroup appears very limited,
which raises the question of the role of SCT in these
patients. However, this observation was based on a limit-
ed number of patients and it was difficult to draw any
conclusions as to whether the dismal outcomes were driv-
en by -5/5q- itself or by the combination of -5/5q- with
abn(17p) or TP53 mutations. In addition, the frequent
association of -5/5q- with abn(17p) suggests co-operation
between TP53 deletion/mutations and loss of putative
tumor suppressor genes localized in the commonly delet-
ed 5q region.17-19  However, -5/5q- is also well-represent-
ed in patients with MK and complex karyotype (CK)
without abn(17p). The interaction observed between 
-5/5q- and abn(17p) in our previous dataset raised the
question of the impact of other additional adverse cytoge-
netic abnormalities such as monosomy 7 or deletion 7q 
(-7/7q-), abn(17p), CK and MK on the outcomes of AML
with -5/5q- after SCT, and this formed the rationale for
our current retrospective study.
Methods
Patient selection and data collection  
This is a retrospective registry-based analysis on behalf of the
Acute Leukemia Working Party (ALWP) of the European Society
for Blood and Marrow Transplantation (EBMT). The EBMT is a
non-profit, scientific society representing more than 600 trans-
plant centers, mainly in Europe, that are required to report all
consecutive stem cell transplantations and their follow up once
a year. Data are entered, managed and maintained in a central
database with internet access; each EBMT center is represented
in this database. Audits are routinely performed to determine
the accuracy of the data. Patients or legal guardians provide
informed consent authorizing the use of their personal informa-
tion for research purposes. The study was approved by the
ALWP review board.
Eligibility criteria for the study included all patients >18 years
with de novo or secondary AML transplanted between 1st January
2000 and 31st December 2015 from an HLA-matched sibling or a
fully-matched (10/10) unrelated donor. Patients undergoing sec-
ond transplantation, as well as patients receiving a haplo-identi-
cal or cord-blood transplantation, were excluded. We further
selected patients harboring -5/5q- and having a full karyotype
report within the database in order to study the prognostic effect
of additional cytogenetic features. A total of 501 patients from
148 centers met the study inclusion criteria and have been
selected for further analysis. Myeloablative conditioning (MAC)
and reduced-intensity conditioning (RIC) have been defined
elsewhere.20 
The following variables were selected and included in the
analysis: year of transplantation, age, gender, white blood cell
count (WBC) at diagnosis, number of induction courses to
achieve complete remission (CR), status at transplantation, time
from diagnosis to SCT, type of conditioning regimen, use of
total body irradiation (TBI), in vivo T-cell depletion (including
both anti-thymocyte globulins and alemtuzumab),
cytomegalovirus (CMV) status of donor and recipient, donor
type, source of stem cells, Karnofsky performance status (KPS) at
transplantation, engraftment, presence of acute and chronic
graft-versus-host disease (GvHD), and grade of acute GvHD. For
the analysis of additional cytogenetic abnormalities, we includ-
ed in our analysis the presence of abn(17p), -7/7q-, MK and CK
classified according to cytogenetic status according to Medical
Research Council UK criteria.5  MK has been defined according
to Breems et al.,13 and CK was defined by the presence of  >3
chromosomal abnormalities.
Statistical analysis and end point definitions
The primary end point was LFS. Secondary end points included
relapse incidence (RI), non-relapse mortality (NRM), overall sur-
vival (OS), acute and chronic GvHD, and refined GvHD-
free/relapse-free survival (GRFS). All outcomes were measured
from the time of transplant. LFS was defined as survival without
relapse; patients alive without relapse were censored at the time
of last contact. OS was based on death from any cause. NRM was
defined as death without previous relapse. GRFS was defined as
survival without grade 3-4 acute GvHD, extensive chronic GvHD,
relapse or death.21 Surviving patients were censored at the time of
last contact. The probabilities of OS, LFS, and GRFS were calculat-
ed by the Kaplan-Meier test, and those of acute and chronic
GvHD, NRM, and relapse by the cumulative incidence estimator
to accommodate competing risks. For NRM, relapse was the com-
peting risk, and for relapse, the competing risk was NRM. For
acute and chronic GvHD, death without the event and relapse
were the competing risks. 
For all univariate analyses, continuous variables were catego-
rized and the median value was used as a cut-off point. A Cox pro-
portional hazards model was used for multivariate regression
including factors associated with LFS in univariate analysis and
individual cytogenetic abnormalities. Finally, we defined four
groups according to the presence of CK, MK and the presence or
not of individual cytogenetic abnormalities significantly associat-
ed with the outcome. Patients', disease and transplant-related
characteristics for the four groups were compared by using χ2 sta-
tistics for categorical variables and the Kruskall-Wallis test for con-
tinuous variables. Factors differing in distribution between the
groups or conceptually important were included in the final Cox
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model. We performed a first multivariate analysis including the
following individual cytogenetics: abn(11q23), abn(17p) and 
-7/7q-.  Then, MK and CK were added to the same model and
thereafter we performed a stepwise selection for the cytogenetics
variables (P in/out =0.10). Abn 17p, MK and CK remained in the
Cox model for OS. Abn 17p and MK also remained in the Cox
model for relapse, LFS and GRFS. The final Cox model contained
all variables that were selected for at least one end point.
Proportional hazards assumptions were checked systematically
using the Grambsch-Therneau residual-based test. All interactions
between cytogenetics groups and other co-variates were tested.
Results were expressed as hazard ratio (HR) with 95% confidence
interval (CI). Statistical analyses were performed with SPSS 24.0
(SPSS Inc., Chicago, IL, USA) and R 3.4.1 [R Core Team (2017). R:
A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria. URL:
https://www.R-project.org/.]  
Results
Patients’ characteristics
Patients’ characteristics are summarized in Table 1. Five
hundred and one patients met the study inclusion criteria.
Median follow up was 57 months [Interquartile Range
(IQR): 27-116 months] and median age was 55-years old
(range: 18-75 years). The main MAC regimen was the
combination of cyclophosphamide with TBI followed by
cyclophosphamide and busulfan, or fludarabine and
busulfan. The main RIC regimen was the association of
fludarabine and busulfan, followed by fludarabine and
low-dose TBI, or fludarabine and melphalan. The most
frequent GvHD prophylaxis was the association of
cyclosporine and methotrexate (44%) followed by
cyclosporine and mycophenolate mofetil (29%).
Additional cytogenetic abnormalities besides -5/5q are
illustrated in Figure 1. The vast majority of the patients
showed a CK (87%) and/or MK (67%) in combination
with -5/5q-. Patients also showed frequent association
with abn(17p) (39%) and -7/7q- (37%), although the vast
majority of these additional cytogenetic features were
observed in the context of a complex or monosomal kary-
otype. Very few patients presented with abn(3q26) (n=22)
or abn(11q23) (n=42). Most of those adverse cytogenetic
features were not present as a single additional abnormal-
ity but rather existed in combination. 
Transplantation outcomes: relapse incidence, 
non-relapse mortality, leukemia-free survival, overall
survival and graft-versus-host disease in the entire
cohort
The 2-year cumulative incidence of relapse in the overall
series was 59.9% (95%CI: 55.3-64.2) (Online
Supplementary Figure S1A), and the median time to relapse
was four months (IQR 0.2-130). In univariate analysis, a
matched sibling donor (MSD), and the presence of addi-
tional cytogenetic abnormalities defined as CK, MK and
abn(17p) were all associated with an increased RI (Table
2). The 2-year probability of NRM was 19.9% (95%CI:
16.4-23.7) (Online  Supplementary Table  S1B). NRM was
strongly associated with donor type and disease status in
univariate analysis. None of the additional cytogenetic
events impacted NRM (Table 2). 
The 2-year probability of LFS in this entire cohort was
20.2% (95% CI: 16.4-23.9) (Online  Supplementary Figure
S1C). In univariate analysis, we found that younger age
(< 55-year old), being in first complete remission (CR1),
better KPS (>80%) and administration of MAC were all
significantly associated with better LFS. CK, MK, abn(17p)
and -7/7q- also impacted on LFS (Table 2). The 2-year OS
was 27% (95%CI: 22.8-31.2) (Online  Supplementary Figure
S1D). Similarly to LFS, younger age (<  55-year old), being
in CR1, better KPS (>80%) and administration of MAC led
to better OS in univariate analysis. Notably, CK, MK,
abn(17p) and -7/7q- impacted prognosis (Table 2). 
The cumulative incidence of grade II-IV acute GvHD
was 29.3% (95%CI: 25.2-33.4) and the 2-year cumulative
incidence of chronic GvHD was 27.3% (95%CI: 23.2-
31.5), leading to a 2-year probability of GRFS of 13.1%
(95%CI: 10-16.3). In univariate analysis, the use of MUD
and not being in remission at SCT were associated with a
higher incidence of grade II-IV acute GvHD. In contrast,
advanced disease status was associated with a lower risk
of chronic GvHD, a fact probably due to the high risk of
early relapse among patients not transplanted in remis-
sion. A female donor to a male recipient led to higher inci-
dence of chronic GvHD in univariate analysis. The pres-
ence of additional cytogenetic abnormalities was not asso-
X. Poiré et al.
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Table 1. Patients’ characteristics from the entire cohort (n=501).
Median follow-up (range)                                                   21 months (2-173)
Median age (range)                                                                55 years (18-75)
Time from diagnosis to SCT (range)                                5 months (0.1-24)
Median year of SCT (range)                                                 2010 (2000-2015)
Disease status at SCT, N (%)
CR1                                                                                                  338 (68%)
CR2/CR3                                                                                           21 (4%)
Active disease                                                                              142 (28%)
Secondary AML, N (%)                                                                 104 (21%)
Donor type, N (%)                                                                 224/277 (45%/55%)
MSD/MUD                                                                                                 
Patients’ gender, N (%)                                                       271/230 (54%/46%)
M/F                                                                                                              
Female donor to male recipient, N (%)                                   92 (19%)
KPS ≥ 80%, N (%)                                                                          447 (94%)
Patient CMV positive, N (%)                                                       314 (64%)
Donor CMV positive, N (%)                                                        254 (52%)
Conditioning intensity, N (%)
MAC/RIC                                                                                  223/278 (45%/55%)
Missing                                                                                                    2
Conditioning regimen, N (%)
Busulfan-based                                                                            225 (45%)
TBI-based                                                                                      139 (28%)
Fludarabine-Busulfan                                                                 143 (29%)
Fludarabine Melphalan                                                                40 (8%)
Stem cell source, N (%)
BM/PB                                                                                      82/419 (16%/84%)
In vivo TCD, N (%)                                                                        282 (57%)
ATG                                                                                                 246 (49%)
Alemtuzumab                                                                                  36 (7%)
Missing                                                                                                   7
SCT: allogeneic stem cell transplantation; N: number; CR1: first remission; CR2: second
remission; CR3: third remission; AML: acute myeloid leukemia; MSD: matched sibling
donor; MUD: matched unrelated donor; M: male; F: female; KPS: Karnofsky’s perform-
ance status; CMV: cytomegalovirus; MAC: myeloablative conditioning regimen; RIC:
reduced-intensity conditioning regimen; BM: bone marrow; PB: peripheral blood; TCD:
T-cell depletion; ATG: anti-thymocyte globulin.
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Table 2. Univariate analysis of additional cytogenetic abnormalities.
                                                  RI                                      NRM                                   LFS                                 OS                                            GRFS
                         2y (%, 95%CI)           P           2y (%, 95%CI)        P          2y (%, 95%CI)      P       2y (%, 95%CI)            P            2y (%, 95%CI)            P
CK
Yes                         62 (57-67)              0.004              20 (16-24)            0.7               18 (14-21)       0.0007        22 (18-27)             <0.0001             11 (8-14)                0.001
No                          44 (31-56)                                     19 (11-30)                                 37 (25-49)                          56 (44-69)                                       26 (15-37)
MK
Yes                         64 (57-69)             0.0004            20 (15-24)           0.56              16 (12-20)       0.0001        22 (17-27)              0.0003               10 (7-14)                0.002
No                          51 (43-59)                                     21 (15-28)                                 28 (21-36)                          38 (30-46)                                       19 (13-26)                   
Abn(17p)
Yes                         66 (58-72)               0.02               22 (16-28)           0.44               13 (8-18)      <0.0001      16 (11-22)             <0.0001              7 (3-10)                0.0002
No                          56 (50-62)                                     19 (15-24)                                 25 (20-30)                          34 (28-39)                                       17 (13-22)                   
-7/7q-
Yes                         62 (54-68)               0.28               22 (16-28)           0.36              17 (11-22)         0.02          20 (14-26)               0.002                10 (6-14)                 0.01
No                          59 (53-64)                                     19 (15-24)                                 22 (17-27)                          31 (26-37)                                       15 (11-19)
Abn3q26
Yes                         68 (37-87)               0.23                15 (3-35)            0.92               16 (0-35)          0.24           13 (0-29)                 0.16                 19 (0-38)                 0.73
No                          60 (55-64)                                     20 (17-24)                                 20 (17-24)                          28 (23-32)                                       13 (10-16)
Abn11q23
Yes                         54 (37-69)               0.42                19 (8-34)            0.95              26 (12-41)         0.21          35 (18-51)                0.18                 19 (7-32)                 0.04
No                          60 (56-65)                                     20 (16-24)                                 20 (16-23)                          26 (22-30)                                        13 (9-16)                 0.04
CK: complex karyotype; MK: monosomal karyotype; abn(17p): 17p abnormalities; -7/7q-: monosomy 7 or deletion 7q; abn3q26: abnormalities of chromosome 3q26; abn11q2:
abnormalities of 11q2; RI: relapse incidence; 2y: 2 years; CI: confidence interval;  NRM: non-relapse mortality; LFS: leukemia-free survival; OS: overall survival; GRFS: graft-versus-
host disease and relapse-free survival.
Figure 1. Additional cytogenetic abnormalities. Distribution of additional cytogenetic abnormalities. Only 47 patients harbored -5/5q- without -7/7q-, CK, MK or
abn(17p). The vast majority of the patients showed a CK (87%) and/or MK (67%) in combination with -5/5q-. The main groups were the combination of CK, MK and
abn(17p), the association of MK and CK and the patients with CK. The dark blue circles illustrate patients with -7/7q- among the different cytogenetic groups.
ciated with the risk of developing acute or chronic GvHD.
The factors associated with GRFS were the same as those
described for LFS and OS (see above and Table 2). The
main cause of death was disease-related (61%), followed
by infections (16%) and GvHD (13%).
The multivariate analysis performed in the entire cohort
confirmed the strong impact of disease status at the time
of transplantation on RI, NRM, LFS and OS (Online
Supplementary Table  S1). Increasing age was associated
with higher NRM, which translated into significantly
worse LFS and OS without impacting RI. The use of MUD
was associated with higher NRM with no effect on OS. A
good performance status at SCT was associated with less
relapse and improved LFS and OS. Conditioning intensity
did not impact any SCT outcome parameters in multivari-
ate analysis. While active disease at SCT and MUD were
associated with higher incidence of grade II-IV GvHD, no
factor was associated with chronic GvHD in multivariate
analysis (Online  Supplementary Table  S2). In our stepwise
selection of cytogenetic variables (as described in the
methods), -7/7q- lost any significance on outcomes and
we kept only CK, MK and abn(17p) in our final multivari-
ate model. There was a significant correlation between
Abn(17p) and decreased LFS, OS and GRFS. 
Outcomes by cytogenetic subgroups
In order to elucidate the impact of additional cytogenet-
ic abnormalities on outcomes of patients with AML and 
-5/5q-, we defined four different subgroups within our
entire cohort in a hierarchical manner according to the
X. Poiré et al.
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Figure 2. Relapse incidence (RI), non-relapse mortality (NRM), leukemia-free survival (LFS) and overall survival (OS) by cytogenetic groups. The 2-year cumulative
incidence of relapse increased significantly from the “none group” up to the “abn(17p) group”, reaching 45.3% [95% CI: 29.9-59.5], 52.7% [95% CI: 40.9-63.1],
61.5% [95% CI: 53.5-68.6] and 65.7% [95% CI: 58.1-72.3] in the none, CK, MK and abn(17p) groups, respectively (P=0.006) (A). The 2-year probability of NRM was
similar across the four groups, reaching 19.9% [95% CI: 16.4-23.7] (P=0.86) (B). The 2-year probability of LFS was 39.4% [95% CI: 24.8-54] for the “none group”,
25.4% [95% CI: 15.6-35.3] for the “CK group”, 19.8% [95% CI: 13.5-26.1] for the “MK group” and 12.6% [95% CI: 7.5-17.7] for the “abn(17p) group” (P<0.001) (C).
The 2-year probability of OS decreased significantly from the “none group” down to the “abn(17p) group”, reaching 59.7% [95% CI: 45.2-74.2], 31% [95% CI: 20.5-
41.6], 26.5% [95% CI: 19.4-33.5] and 16.3% [95% CI: 10.5-22] in each group respectively (P<0.001) (D).
A B
C D
presence of CK, MK and abn(17p), based on their prognos-
tic impact shown in univariate and multivariate analysis
and their capability to distinguish biologically and clinical-
ly meaningful cytogenetic categories. Our study contains
154 monosomy 5 and 347 deletion 5q. We decided to
study -5 and 5q- together in order to analyze the impact of
MK separately from -5. Indeed, all of our -5 patients
except one fulfilled the definition of MK. Thus, the 
“5q sole group” contained 47 patients with 5q abnormali-
ties but absence of additional -7/7q-, abn(17p), CK or MK.
Notably, no case of -5 was included in this group. The “CK
group” included 90 patients who fulfilled the definition of
CK but without abn(17p) or MK. Only one patient with -
5 was included in this group. The “MK group” was com-
prised of the group of patients with -5/5q- within a MK
with the exception of abn(17p), and finally, the “abn(17p)
group” encompassed the combination of -5/5q- with
abn(17p) regardless of the presence of other cytogenetic
features. Due to the lack of significance of -7/7q- in our
multivariate analysis, this abnormality was not taken into
account in our prognostic classification. Patients’ charac-
teristics were well balanced between those four cytoge-
netic subgroups (Online Supplementary Table S3). The 
2-year probability of NRM was similar across the four
groups (P=0.86), but the 2-year cumulative incidence of
relapse increased significantly from the “5q sole” up to the
“abn(17p)” group, reaching 45.3% (95%CI: 29.9-59.5),
52.7% (95%CI: 40.9-63.1), 61.5% (95%CI: 53.5-68.6) and
65.7% (95%CI: 58.1-72.3) in the 5q sole, CK, MK and
abn(17p) groups, respectively (P=0.006) (Figure 2A and B).
Median time to relapse was 6.2 months (IQR: 3.5-16.3),
for the “5q sole group”, 4.7 months (IQR: 2.3-8) for the
“CK group”, 4.5 months (IQR: 2.3-9.1) for the “MK group”
and 3.9 months (IQR: 2.2-8.7) for the “abn(17p) group”
(P=0.12). This different RI across cytogenetic subgroups
also determined other important outcomes. Thus, the 
2-year probability of LFS was 39.4% (95%CI: 24.8-54) for
the “5q sole group”, 25.4% (95%CI: 15.6-35.3) for the “CK
group”, 19.8% (95%CI: 13.5-26.1) for the “MK group” and
12.6% (95%CI: 7.5-17.7) for the “abn(17p) group”
(P<0.001) (Figure 2C). The 2-year probability of OS also
decreased significantly from the “5q sole group” down to
the “abn(17p) group”, reaching 59.7% (95% CI: 45.2-74.2,
31%  [95% CI: 20.5-41.6], 6.5% [95% CI: 19.4-33.5] and
16.3% [95% CI: 10.5-22] in each group, respectively
(P<0.001) (Figure 2D). The 2-year probability of GRFS fol-
lowed the same trend, with 26.5% [95% CI: 13-39.9] for
the “5q sole group”, 17% [95% CI: 8.5-25.4] for the “CK
group”, 14.2% [95% CI: 8.7-19.7] for the “MK group” and
only 6.6% [95% CI: 2.8-10.4] for the “abn(17p) group”
(P<0.001) (Online Supplementary Figure S2). In contrast, the
cumulative incidence of grade II-IV acute GvHD and the
2-year cumulative incidence of chronic GvHD were not
different across the four groups (P=0.33 and P=0.8, respec-
tively).  
In multivariate analysis, taking the “5q sole group” as a
reference, the “CK group” did not show any significant
difference in RI, NRM, LFS, OS, LFS and GRFS. In con-
trast, patients in the “MK group” and “abn(17p) group”
experienced higher incidence of RI and lower LFS, OS and
GRFS compared to the “5q sole group” (Table 3). To min-
imize the strong impact of disease status on outcome, we
decided to run the univariate by cytogenetic subgroups
focusing on the 338 patients transplanted in CR1. The
“MK group” and “abn(17p) group” had the same negative
impact on RI, LFS and OS (Figure 3). As detailed above,
the presence of -7/7q- was excluded from the “5q sole
group”, but was present in 21% of the “CK group”, 51%
of the “MK group”,  and 40% of the “abn(17p) group”.
Given the high overlap between the -7/7q and the “MK
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Table 3. Multivariate analysis using a Cox proportional hazard model
by cytogenetic subgroups. Only variables with a P<0.05 in univariate
analysis.
                                                    P                      HR                95% CI
RI
Age (per 10 year)                         0.65                        1.03                  0.91-1.16
MUD vs. MSD                                 0.44                        0.91                  0.71-1.16
Active disease vs. CR               <0.0001                    1.73                  1.32-2.27
KPS ≥ 80%                                      0.06                        0.64                  0.40.1.01
RIC vs.MAC                                    0.11                        1.25                  0.95-1.63
5q sole (reference)                                                      1
CK                                                    0.67                        1.12                  0.66-1.91
MK                                                    0.02                        1.74                   1.09-2.8
Abn(17p)                                       0.002                       2.11                  1.32-3.37
NRM
Age (per 10 year)                       0.0007                      1.48                  1.18-1.85
MUD vs.MSD                                 0.001                       2.07                  1.32-3.25
Active disease vs.CR                   0.002                       2.00                   1.3-3.08
KPS ≥ 80%                                      0.22                        0.61                  0.27-1.35
RIC vs.MAC                                    0.23                        0.76                  0.48-1.19
5q sole (reference)                                                      1
CK                                                    0.96                        1.02                  0.46-2.26
MK                                                    0.63                        1.19                  0.58-2.47
Abn(17p)                                        0.22                        1.55                  0.76-3.14
LFS
Age (per 10 year)                         0.03                        1.12                  1.01-1.25
MUD vs.MSD                                  0.35                        1.11                  0.90-1.36
Active disease vs.CR                <0.0001                     1.8                   1.43-2.27
KPS ≥ 80%                                      0.03                        0.64                  0.43-0.96
RIC vs.MAC                                     0.44                         1.1                   0.87-1.38
5q sole (reference)                                                      1                            
CK                                                     0.7                         1.09                  0.70-1.69
MK                                                    0.03                        1.57                  1.05-2.33
Abn(17p)                                       0.001                       1.93                  1.30-2.84
OS
Age (per 10 year)                        0.006                       1.16                   1.04-1.3
MUD vs.MSD                                  0.24                        1.14                  0.92-1.41
Active disease vs. CR               <0.0001                    1.88                  1.49-2.38
KPS ≥ 80%                                      0.04                        0.66                  0.44-0.98
RIC vs.MAC                                     0.46                        1.09                  0.86-1.38
5q sole (reference)                                                      1                            
CK                                                    0.25                        1.31                  0.83-2.08
MK                                                   0.006                       1.80                  1.19-2.72
Abn(17p)                                      0.0002                      2.19                  1.45-3.30
GRFS
Age (per 10 year)                         0.08                        1.14                  1.04-1.26
MUD vs.MSD                                  0.18                        1.15                  0.94-1.41
Active disease vs.CR                <0.0001                    1.64                  1.31-2.04
KPS ≥ 80%                                      0.06                        0.68                  0.46-1.01
RIC vs. MAC                                    0.77                        1.03                   0.82-1.3
5q sole (reference)                                                      1
CK                                                    0.14                        1.37                  0.90-2.09
MK                                                   0.008                       1.69                  1.15-2.48
Abn(17p)                                      0.0003                      2.03                  1.39-2.98
HR: hazard ratio; CI: confidence interval; RI: relapse incidence; MUD: matched unrelat-
ed donor ; MSD: matched sibling donor; CR: complete remission; KPS: Karnofsky’s per-
formance status; RIC: reduced-intensity conditioning; MAC: myeloablative condition-
ing; abn(17p): 17p abnormalities; CK: complex karyotype; MK: monosomal karyotype;
NRM: non-relapse mortality; LFS: leukemia-free survival; OS: overall survival; GRFS:
graft-versus-host and relapse-free survival.
group”, we then performed a univariate analysis within
the “MK group” comparing the outcome between patients
with presence or absence of additional -7/7q- and did not
find any significant impact on RI, NRM, LFS, OS and
GRFS. We also looked at the impact of MK within the
“abn(17p)”; MK lost its negative impact in this very high-
risk subgroup, even though the group of abn(17p) patients
without MK was rather small (n=26) (data not shown).
Discussion
-5/5q- is a common finding in AML, consistently asso-
ciated with poor outcomes after standard chemotherapy
with long-term overall survival of about 5%.5,22 SCT has
been shown to significantly improve the outcome of
high-risk AML subsets, with a probability of disease cure
in the range of 40%.1,8,9,23 Nonetheless, in our large cohort
of  501 AML patients harboring -5/5q undergoing first
SCT, the 2-year probability of OS and LFS was only 27%
and 20%, respectively, outcomes which clearly appear
inferior to those reported for other high-risk cytogenetic
AML,8 suggesting an independent deleterious effect of -
5/5q- on transplant outcome. Indeed, in the EBMT reg-
istry, we found 3,021 patients with adverse cytogenetics
according to the MRC classification with the exception of
-5/5q-, and we found a 2-year OS and LFS of 43% and
37%, respectively. In contrast, our results resemble those
of patients with MK AML.24-26 Indeed, most of the
patients in our cohort harbored additional adverse cyto-
X. Poiré et al.
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Figure 3. Relapse incidence (RI), non-relapse mortality (NRM), leukemia-free survival (LFS) and overall survival (OS) by cytogenetic groups in patients in first remis-
sion. The 2-year cumulative incidence of relapse increased significantly from the “none group” up to the “abn(17p) group”, reaching 48.9% [95% CI: 30.9-64.7],
43.9% [95% CI: 29.6-57.4], 58.7% [95% CI: 48.7-67.4] and 70.1% [95% CI: 60.6-77.8] in the none, CK, MK and abn(17p) groups, respectively (P=0.006) (A). The 2-
year probability of NRM was similar across the four groups, reaching 19.9% [95% CI: 16.4-23.7] (P=0.87) (B). The two-year probability of LFS was 34.7% [95% CI:
18.6-50.9] for the “none group”, 33.5% [95% CI: 19.9-47] for the “CK group”, 23.9% [95% CI: 15.7-32] for the “MK group” and 13.6% [95% CI: 7-20.2] for the
“abn(17p) group” (P<0.001) (C). The 2-year probability of OS decreased significantly from the “none group” down to the “abn(17p) group”, reaching 58.5% [95% CI:
42.3-74.6], 36.5% [95% CI: 22.6-50.3], 33% [95% CI: 23.9-42] and 16.1% [95% CI: 8.9-23.3] in each group, respectively (P<0.001) (D).
A B
C D
genetic features, such as MK (67%), which may have
been confounded with the true impact of -5/5q-.
Moreover, inferior outcomes of this cohort may also be
explained by the fact that about 30% of our patients had
active disease at the time of SCT, which appears, as
expected, to be a strong predictor for worse outcomes in
multivariate analysis.8 Nevertheless, even when focusing
on patients in CR1, the observed outcomes in the current
cohort are still in the range of 25% at two years, suggest-
ing that our population represents a higher-risk group.
Not surprisingly, younger age and a better performance
status were both associated with better OS and LFS in
line with previously published data,1,27,28  but this observa-
tion should be weighed against the underlying selection
bias inherent in such a registry-based study. Conditioning
intensity lost all impact on outcomes in multivariate
analysis. This observation has been confirmed in other
studies where the benefit of conditioning intensity was
lost in chemorefractory disease, such as MK AML and
those involving TP53 deregulation.26,29
The main objective of our study was to evaluate the
impact of additional cytogenetic abnormalities in a cohort
of AML patients with -5/5q-. The presence of -5/5q- is
rarely an isolated event in AML as it is frequently associ-
ated with other adverse cytogenetic features, such as CK,
MK, -7/7q- or abn(17p).5,22,30 The independent impact of 
-5/5q- was questioned by Breems et al. in the first report
on MK, in which any single monosomy carried a better
outcome than the full definition of MK,13,15,31 with no spe-
cific effect for -5/5q-. More recently, Middeke et al.
described 236 high-risk AML patients after SCT, and
found that -5/5q- was associated with worse outcomes
compared to CK and/or MK AML, and that abn(17p)
translated into the worst survival after SCT.32 Those data
suggested that the bad prognosis of MK AML after SCT
was mainly related to the presence of -5/5q- and/or
abn(17p), but these observations have not been complete-
ly confirmed by others.15,33  In our multivariate Cox model,
we found that either the presence of MK or abn(17p)
were both significantly associated with worse OS and
LFS, while CK and -7/7q- had no impact on any outcome
parameter. Most of those additional cytogenetic abnor-
malities and/or characteristics are typically not present as
a single additional event to -5/5q- (Figure 1) making it dif-
ficult to weigh the impact of each individual additional
event. To avoid the confounding effect of largely overlap-
ping cytogenetic categories, we decided to define four
well-delimited groups based on a hierarchical prognostic
effect of MK and additional abn(17p) in -5/5q- AML: the
“5q sole group”, “CK group”, “MK group”, and “abn(17p)
group”. These cytogenetic categorizations allowed us to
confirm the strong deleterious prognostic effect of addi-
tional MK and abn(17p) in this entity in multivariate
analysis. In contrast, we did not observe  differences in
any outcome parameters between the “5q sole group”
and the “CK group” with a relatively better 2-year OS
(close to 40% for patients transplanted in CR1). The addi-
tional cytogenetic abnormalities found in both of those
groups could only be numerical abnormalities and some
structural abnormalities. The weaker prognostic impact
of numerical abnormalities such as trisomy has already
been suggested in other studies.13,34 On the contrary, the
presence of -5/5q- within MK is translated into worse LFS
and OS, which is in agreement with most published
data,24,33 but different from the report from Middeke et al.32
Finally, we confirmed the deleterious effect on outcomes
of the combination of -5/5q- with any abn(17p), which
has been suggested from our previous dataset.16 The
impact of abn(17p) clearly appears stronger than MK, as
MK did not impact outcomes within the “abn(17p)”
group.
Patients with -5/5q- AML in CR1 without MK and/or
abn(17p) appear to benefit from allogeneic SCT, with
long-term survival achieved in more than 40% of the
patients. In contrast, patients harboring the combination
of -5/5q- with abn(17p) represent a very poor subgroup
due to an intrinsic and well-known chemoresistance and
to a potential lack of sensitivity to a GvL effect.16 If SCT
remains the only option for those high-risk patients in
CR1, it should be integrated into a post-transplant inter-
vention program including low-dose decitabine,35 prophy-
lactic donor leukocyte infusions,36,37 a combination of both
or other P53-independent therapeutic agents.
Lenalidomide has been shown to have a specific effect on
myelodysplastic syndrome (MDS) with isolated 5q-
through inhibition of the 5q- clone, leading to 60% hema-
tologic response and 40% cytogenetic response.38-40
However, responses have been much lower in patients
with higher-risk MDS and AML, especially if harboring
CK or MK.38  Combinations with standard chemotherapy
or hypomethylating agents are associated with objective
responses even in patients harboring high-risk features38,41
with the exception of TP53 mutated clones.42,43 Another
option might be to integrate lenalidomide as maintenance
therapy after SCT, but previous experiences raised seri-
ous concerns about an increased risk of acute GvHD.44,45
However, interesting results from the combination of
lenalidomide and azacytidine have been recently pub-
lished.46 
In conclusion, our study, based on a large cohort of
patients with AML and -5/5q- undergoing SCT, showed
that this strategy led to long-term survival in about 20%
of the patients, which seems inferior to other high-risk
AML subsets. One of the largest limitations in this study
might be the lack of centralized cytogenetic analysis and
the selection of patients with an available full cytogenetic
report; an essential requirement for the proposed analy-
sis. Active disease at the time of SCT remains the
strongest prognostic factor of worse survival and precau-
tions have to be taken when bridging these patients to
SCT. Novel therapeutic pre-transplant strategies must be
developed to increase the proportion of patients in remis-
sion before SCT. Finally, we found that the benefit from
SCT in this cytogenetic entity is highly dependent on the
presence of particular additional adverse cytogenetic fea-
tures. Indeed, patients without MK or abn(17p) benefit
the most from SCT, whereas the additional presence of
MK and/or abn(17p) leads to a very poor outcome. SCT
is therefore questionable in this subgroup of patients with
the current standard approach, especially if they are not
in CR1 at the time of SCT. Development of pre-transplant
and post-transplant pharmacological and immunological
interventions to sustain a response in a larger proportion
of patients is urgently needed in these patients.  
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